JENNIFER MORRIS: Open Payments
NPI 1871225540 · GARDENDALE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,133 in 110 payments from 17 companies in 2025. Trend: 2023 $1,318 · 2024 $1,634 · 2025 $2,133
Food & beverage: $2,133
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 13 | $297 |
| AstraZeneca Pharmaceuticals LP | 13 | $230 |
| GlaxoSmithKline, LLC. | 11 | $223 |
| Bayer Healthcare Pharmaceuticals Inc. | 10 | $167 |
| Novo Nordisk Inc | 7 | $166 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 9 | $144 |
| Amgen Inc. | 7 | $140 |
| Dexcom, Inc. | 7 | $129 |
| Corcept Therapeutics | 5 | $118 |
| Paratek Pharmaceuticals, Inc. | 7 | $105 |
Products named: GEMTESA, TRELEGY ELLIPTA, Kerendia, JARDIANCE, FARXIGA, REPATHA, Dexcom G6 Transmitter, Ozempic.
Industry payments across AL — which companies pay providers there.
